Celiac disease (CD) is a systemic disease triggered by gluten ingestion in genetically predisposed individuals. It manifests primarily as an autoimmune enteropathy associated with specific circulating autoantibodies and a human leukocyte antigen haplotype (HLA-DQ2 or HLA-DQ8). It afflicts roughly 1% of the population, though the majority of patients remain undiagnosed. Diarrhea and malabsorption are classic manifestations of CD; however, both children and adults can be paucisymptomatic and present extraintestinal manifestations such as anemia, osteoporosis, and abnormal liver tests. CD screening is not recommended for the general population, and it should be focused on high-risk groups. CD diagnosis is challenging and relies on serological tests, duodenal histology, and genetic testing. Particularly difficult presentations to manage are seronegative patients, seropositive patients without villus atrophy, and patients who have started a gluten-free diet before the diagnostic workup. The only proven treatment is a lifelong gluten-free diet. We present an in-depth review on the physiopathology and management of CD, with a particular emphasis on diagnostic challenges.

A doença celíaca (DC) é uma doença sistémica desencadeada pela exposição ao glúten em doentes geneticamente susceptíveis. Manifesta-se maioritariamente por uma enteropatia auto-imune associada a auto-anticorpos e aos haplotipos HLA-DQ2 ou HLA-DQ8. A DC afecta aproximadamente 1% da população mundial admitindo-se, no entanto, que a maioria dos doentes não esteja diagnosticada. As manifestações clássicas de DC são a diarreia e sintomas de malabsorção, no entanto tanto crianças como adultos podem ser pauci-sintomáticos ou apresentar manifestações extra-intestinais incluindo anemia, osteoporose ou alteração das provas hepáticas. O rastreio de base populacional não está recomendado, devendo o foco ser nos grupos de risco para DC. O diagnóstico de DC é um desafio e assenta em três pilares: testes serológicos, histologia duodenal e testes genéticos. Apresentações particularmente difíceis de manejar são os doentes sero-negativos, doentes sero-positivos sem atrofia vilositária e doentes que iniciam dieta sem glúten antes da marcha diagnóstica. O único tratamento com eficácia comprovada é a dieta sem glúten. Apresentamos uma revisão aprofundada da fisiopatologia e manejo da DC, com particular ênfase nos desafios diagnósticos.

Palavras Chave Doença celíaca, Testes serológicos, Histologia duodenal, Desafios diagnósticos

Celiac disease (CD) is a systemic disease triggered by gluten ingestion, in genetically predisposed individuals. It manifests as an autoimmune enteropathy associated with specific circulating autoantibodies and human leukocyte antigen haplotype (HLA-DQ2 or HLA-DQ8) [1].

Aretaeus of Cappadocia, in 250 A.D., described a chronic perturbation of “pepsis” (i.e., digestion) and “anadosis” (i.e., absorption) resulting in a general debility which was named “celiac diathesis” [2, 3]. The word “celiac” is derived from the Greek “koiliakos,” which means abdominal [4]. However, it was only in 1888 that Samuel Gee [5] published the first modern clinical detailed description of CD. In 1908, in the USA, Christian Herter [6] published a similar description, emphasizing the retardation in growth. For several years, CD was known as Gee-Herter disease [7].

Diet was proposed as a causal contributor since Arateus. In the twentieth century, several diets were advocated, such as the banana diet [8] and the Fanconi diet based on fruits and vegetables [7]. The causal link to grain consumption (wheat, rye, barley, and, to a lesser extent, oats) was described in the forties by the Dutch pediatrician Willem-Karel Dicke. This link came from the observation of the effect of food scarcity on children with CD during the Second World War. Dicke observed that symptoms of children with CD improved when they were not eating bread or grains and worsened after the war ended and these foods reentered their diet [7, 9].

Paulley [10], in 1954, described detailed histological anomalies in the small bowel from surgical specimens (chronic inflammation and atrophy) from patients with CD.

In 1964, Berger et al. [11] reported the presence of serum anti-gliadin antibodies (AGA) in CD. It took up to 20 years for serology be considered a diagnostic criterion [12, 13]. More sensitive and specific serological tests have been identified since then [14, 15].

In 1972, Falchuk et al. [16] described the association between a specific HLA genotype and CD and hypothesized that CD is a consequence of carrying an abnormal immune response gene to gluten. We know now that HLA-DQ2/8 is necessary for the development of CD, making HLA determination the third pillar in the diagnosis of CD [17].

The prevalence of CD varies according to age, gender, and region. A recent meta-analysis estimated a global prevalence of 1.4% by serological tests and 0.7% by intestinal biopsy [18]. This is probably an underestimation of the real prevalence of CD, since it is estimated that only 1 in 5 patients with CD is diagnosed [19]. In some regions, such as Asia and Africa, the number of reported cases of CD is extremely low, even though wheat consumption is increasing [20] and the frequency of CD-associated HLA alleles seems similar to that in Western countries [21]. As such, in Asia, CD is likely to be even less efficiently diagnosed, with less awareness for the asymptomatic forms of the disease [22]. In this millennium, the prevalence of CD seems to have increased by 33%, for unknown reasons, but it is probably associated with environmental factors [18].

Women are 1.5 times more afflicted than men [18]. The incidence of CD is approximately 2 times more frequent in children than in adults, with a second peak in incidence between 50 and 69 years [23].

Genetics are a main factor in the risk for CD, with over 40 genetic loci associations besides the HLA-DQ2/8 haplotype [24].

Environmental factors have been studied as risk factors for CD [25-27]. The association between age at gluten introduction and CD is controversial [28-32]; however, current recommendations advise gluten introduction between 4 and 12 months of age [33]. The amount and pattern of gluten consumption may have a role and may account for the different prevalence rates of CD across Europe [34].

Breastfeeding does not seem to protect from CD [28, 32, 35-37]. Recurrent respiratory infections (in infants) and gastrointestinal infections (rotavirus and adenovirus in children and Campylobacter in adults) seem to be associated with CD [25, 26, 38], though the evidence is weak [39].

Lastly, high-risk groups for CD include first-degree relatives of CD patients [40] (with a prevalence up to 7.5%) [41], and patients with type 1 diabetes mellitus (T1DM) [42] or other autoimmune diseases [43], IgA deficiency [44], and chromosomopathies such as Down syndrome [45] and Turner syndrome [46].

CD results from an intense immune response to gluten leading to small bowel injury with consequent malabsorption and autoimmune phenomena [47].

Gluten consists of a group of proteins from Gramineae of the Triticiae tribe, particularly wheat, rye, and barley. Oats are phylogenetically more distant (Aveneae tribe) but share sufficient similarities to induce symptoms in some patients. Rice, maize, sorghum, and millet are distant enough not to trigger CD [48]. Gluten is the Latin word for “glue,” owing its name to its viscoelastic and adhesive properties [26]. The word gluten is widely used to refer to disease-inducing Gramineae proteins; however, strictly speaking, gluten specifically refers to proteins from wheat. Similar proteins in rye are secalins, and in barley they are hordein [49]. Wheat gluten contains 2 major protein components, i.e., monomeric water-soluble gliadins and multimeric water-insoluble glutenins [50].

Gluten peptides are highly enriched in proline and glutamine. Gastrointestinal proteases are deficient in prolyl-endopeptidase activity. As such, the high-proline content makes gluten resistant to gastrointestinal cleavage, allowing the subsistence of polypeptides with up to 33 amino acids [51]. This increases gluten’s immunogenicity, since major histocompatibility complex (MHC) II molecules only present peptides at least 9 amino acids long [52].

Gluten peptides are not freely absorbed and need a disruption in the epithelial barrier to translocate into the lamina propria, where antigen-presenting cells (APC) reside. That may occur through a damaged epithelium, induced by transient intestinal infection, drug-induced inflammation (e.g., nonsteroidal anti-inflammatory drugs), or dysbiota-induced disassembly of enterocyte tight junctions. Alternatively, gluten can cross the epithelium in a transcellular pathway through binding of gluten-secretory IgA complexes to the transferrin receptor CD71 or inside dendritic cells that cross the epithelium [17, 50, 53-55].

MHC-II molecules bind preferentially to peptides with negatively charged amino acids. Even though gluten peptides have very few charged amino acids, they are highly susceptible to deamidation on their glutamine residues to negatively charged glutamate by tissue transglutaminase (tTG) [52]. Deamidation significantly increases the stability of the gluten-MHC complex, increasing their immunogenicity [56].

APC present deamidated gluten peptides bound to a specific MHC class II that map to the HLA-DQ locus. That locus codifies antigen-presenting glycoproteins that are heterodimers constituted by a α-chain (encoded by the DQA1 allele) and a β-chain (encoded by the DQB1 allele). Only HLA-DQ2.5, DQ2.2, and DQ8 (and probably DQ7.5) bind to deamidated gluten peptides, and so their presence is necessary for the development of CD. However, it is not a sufficient condition, since these haplotypes are also found in 40% of the general population [53, 57]. Nonetheless, about 90% of CD patients express HLA-DQ2.5 and roughly 10% express HLA-DQ2.2 or HLA-DQ8 [58]. HLA-DQB1*02, present in HLA-DQ2.5 and HLA-DQ2.2, confers a higher risk for CD compared to the presence of HLA-DQB1*03, present in HLA-DQ8. The frequency of HLA-DQB1*02 seems to be even higher in CD patients with T1DM [59]. Furthermore, there is a dose effect for HLA-DQ2.5, since homozygous individuals have a 5-fold increased risk for CD and for severe disease [60]. Haplotypes, HLA, and their risk are shown in Table 1.

Table 1.

HLA and the risk of CD

HLA and the risk of CD
HLA and the risk of CD

APC (dendritic cells and macrophages) present the complex MHC-II-deamidated gliadin to CD4+ T cells, inducing a proinflammatory phenotype in T cells [61]. Activated CD4+ T cells promote differentiation of B cells into plasma cells and release proinflammatory cytokines such as interferon-γ and interleukin-21 that activate intraepithelial CD8+ T cells [17, 58]. Interleukin-15 further promotes intraepithelial CD8+ T cell differentiation into a cytotoxic NK cell-like phenotype, damaging enterocytes [61]. Activated CD4+ T cells also secrete tumor necrosis factor-α, which acts on intestinal fibroblasts inducing their secretion of: (1) matrix metalloproteinases (contributing to mucosal destruction by dissolution of connective tissue) [62] and (2) epithelial mitogen keratinocyte growth factor (contributing to crypt epithelial cells hyperplasia) [63].

Lastly, tTG-deamidated gluten complex may bind to receptors allowing internalization into specific B cells, which then act as APC to CD4+ T cells, further fueling the immune response. Conversely, those B cells may differentiate into plasma cells, explaining why specific anti-tTG antibody production only occurs under a gluten-containing diet [64]. The pathophysiology of CD is summarized in Figure 1.

Fig. 1.

Pathogenesis of CD. Gluten peptides reach the lamina propria through a leaky gut, with increased intestinal permeability, which may be due to drug-induced inflammation or dysbiota-induced disassembly of enterocyte tight junctions. Gluten peptides are then deamidated by tTG, which allows them to be presented to CD4-T cells by APC that exhibit MHC class II molecules encoded by the haplotypes HLA-DQ2 or HLA-DQ8. This will trigger T-helper 1 and T-helper 2 immune responses that result in mucosal cytotoxicity and inflammation, as well as autoimmune extraintestinal phenomena.

Fig. 1.

Pathogenesis of CD. Gluten peptides reach the lamina propria through a leaky gut, with increased intestinal permeability, which may be due to drug-induced inflammation or dysbiota-induced disassembly of enterocyte tight junctions. Gluten peptides are then deamidated by tTG, which allows them to be presented to CD4-T cells by APC that exhibit MHC class II molecules encoded by the haplotypes HLA-DQ2 or HLA-DQ8. This will trigger T-helper 1 and T-helper 2 immune responses that result in mucosal cytotoxicity and inflammation, as well as autoimmune extraintestinal phenomena.

Close modal

The clinical spectrum of CD is broad, which accounts for the challenging diagnosis. Classical gastrointestinal manifestations are more common in children, whereas adults tend to be paucisymptomatic [25]. Classical manifestations are chronic diarrhea (in 35%), abdominal pain (28%), and weight loss (22%) [53, 65]. CD can also present paradoxically with chronic constipation (20%), abdominal distension (20%), gastroesophageal reflux (12%), and even obesity [25, 53].

The most common extraintestinal manifestations are decreased bone mineralization (osteopenia in 50–70% and osteoporosis in 5.5% of cases), anemia (32%), arthralgia (29%), fatigue (26%), and neurological symptoms (20%), particularly gluten ataxia and peripheral neuropathy [53, 66]. Gluten ataxia is an autoimmune injury of the cerebellum, induced by gluten ingestion, which manifests with a typical serology and abnormal gait, muscle coordination, and fine control of voluntary movements, as well as cerebellum atrophy on magnetic resonance imaging (up to 60%). The mean age at onset is around 50 years [67] and the effect of a gluten-free diet (GFD) is controversial [68-71]. Gluten neuropathy is a sensitive neuropathy that is associated with serological evidence of CD, which initially affects the hands and feet but usually progresses. The mean age at diagnosis is 55 years and a GFD can improve symptoms regardless of the presence or absence of enteropathy [71].

CD can also manifest with hypertransaminasemia (9–14%), recurrent aphthous stomatitis, tooth enamel defects, infertility, delayed puberty, and a short stature [53, 66, 72]. Most extraintestinal manifestations improve with a GFD, but an early diagnosis is crucial and some manifestations, such as enamel defects, may be irreversible [66].

CD is associated with many genetic disorders. The prevalence of CD is higher in patients with chromosomopathies (i.e., 5–10% in patients with Down, Turner, and Williams syndromes) [73]. This might be explained by the proinflammatory millieu and impaired function of CD4+ T cells associated with chromosomopathies [46, 74].

Autoimmune glandular diseases, particularly T1DM and thyroid disease, are strongly associated with CD; 10–30% of CD patients have 1 of those 2 autoimmune diseases and up to 7% of patients with autoimmune glandular diseases have CD [25, 75]. In fact, those conditions share a genetic background with a tight link to HLA-DQ2/8 and DR3/4 [75]. Interestingly, the prevalence of autoimmune diseases increases with increasing age at diagnosis, probably as a consequence of a higher duration of exposure to gluten [76].

Herpetiform dermatitis (HD) is a dermatological autoimmune disease that also shares a genetic background with CD. Up to 20% of CD patients develop HD and more than 90% of HD patients have CD. HD diagnosis can be confirmed by skin biopsy demonstrating IgA deposits in the papillary dermis adjacent to the lesion. These patients present anti-tTG as well as IgA anti-epidermal transglutaminase antibodies. HD responds to GFD, although transient treatment with dapsone may be needed [25, 66, 77].

CD patients have an increased risk of hepatic diseases such as steatosis, autoimmune hepatitis, primary biliary cholangitis (at least a 20-fold increase) [78], and primary sclerosing cholangitis (4- to 8-fold increase) [79].

Finally, patients with a selective IgA deficiency present a risk of CD that is 10–20 times higher [80]. The reverse is also true, i.e., IgA deficiency is 10–15 times more frequent in patients with CD [81].

Who to Test?

Current guidelines recommend testing for CD patients with signs, symptoms, or laboratorial evidence of malabsorption, unexplained fatigue, and recurrent mouth ulcers. Furthermore, patients with T1DM or autoimmune thyroid disease should be regularly tested [82, 83]. Importantly, the presence of symptoms is not required for a diagnosis of CD [84].

CD screening is recommended in patients with irritable bowel syndrome, since these patients are 4 times more likely to have CD than the general population, even patients presenting with obstipation [85]. Lastly, first-degree relatives of CD patients should be screened, though there are no recommendations regarding the time interval for rescreening [73].

The following high-risk groups should also be considered for screening: children and adolescents with chromosomopathies and patients with metabolic bone disorders, unexplained neurological symptoms, hypertransaminasemia or infertility, and dental enamel defects [73]. CD screening recommendations are displayed in Table 2.

Table 2.

Current recommendations on CD screening

Current recommendations on CD screening
Current recommendations on CD screening

Population-based screening is not recommended, since it has not been proven that the diagnosis of asymptomatic patients improves their quality of life [87, 88].

Diagnostic Tools

CD diagnosis relies on 3 main pillars, i.e., serological tests, duodenal histology, and genetic testing [89]. The diagnostic algorithm is presented in Figure 2.

Fig. 2.

CD diagnosis flowchart.

Fig. 2.

CD diagnosis flowchart.

Close modal

Anti-tTG IgA is the recommended first-line serological test, as it is the most sensitive test (98%) and has a very good specificity (96%) [47]. Anti-tTG is determined through ELISA, allowing quantitation. Anti-endomysial (EMA) IgA reacts to the same antigen of tTG, but bound to tissue, requiring immunofluorescence in tissue from primate oesophagus or human umbilical cord. As such, EMA is more expensive, technically more challenging, and operator dependent, and it only allows qualitative results [90]. The anti-EMA IgA test is the most specific serological test [91] and it should be used as a confirmatory test, especially when the anti-tTG level is lower than 2 times the upper limit of normal [83, 89]. Anti-tTG and anti-EMA IgG have a low sensitivity and should be interpreted carefully [91].

AGA is not recommended for CD diagnosis due to the low sensitivity and specificity [82, 92]. More recently, anti-deamidated gliadin peptides (DGP), which are assessed by an ELISA assay, have been adopted, particularly IgG that is superior to other IgG antibodies (88% sensitivity and 99% specificity) [91]. Anti-DGP IgG is particularly useful in patients with a selective IgA deficiency [83, 93].

Diagnosis should start with measurement of both anti-tTG IgA and IgA serum levels. Positive anti-tTG IgA should prompt duodenal biopsies to confirm the diagnosis. When the anti-tTG IgA titer is low (4–10 U/mL) with normal IgA levels, anti-EMA IgA should be assessed. Lastly, when IgA <1 mg/dL, IgG antibodies should be assessed (particularly anti-DGP IgG) [90].

All serological tests should be performed under a gluten-containing diet to avoid false-negative results [82]. False-positive results may occur with intestinal infections (e.g., Giardia lamblia) [94], chronic liver disease [95], congestive heart failure [96], and hypergammaglobulinemia [97]. Of note, serological tests have demonstrated high intertest and interlaboratory variability at lower ranges, and this should be confirmed by alternative tests when levels are lower than 10 times the upper limit of normal [84].

All patients with positive serological tests should undergo an upper endoscopy with duodenal biopsies [73]. Endoscopy is also indicated in patients with negative serological tests when the clinical suspicion is high [82].

Endoscopic findings alone present a sensitivity that ranges from 11 to 22% for CD [98]. Some findings, however, are very specific (up to 99%) for mucosal atrophy, i.e., scalloping duodenal folds, fissuring, and a mosaic pattern of the mucosa [99, 100]. Less specific findings are duodenal erosions, loss of folds, nodular mucosa, and enhanced submucosal vessels [99, 101]. The role of advanced endoscopic techniques such as immersion endoscopy [102], NBI [103], iSCAN [104], and confocal endomicroscopy [105] is still unclear [106]. Capsule endoscopy may be useful for patients who refuse endoscopy and in complicated CD [107].

Histology is crucial for the diagnosis of CD in adults, and the way endoscopic biopsies are collected determines their accuracy. At least 4 duodenal biopsies should be collected, since the distribution of lesions is discontinuous [82]. Furthermore, 1 or 2 biopsies should be collected from the duodenal bulb (from the 9 or 12 o’clock position), since it increases (by almost 10%) the sensitivity in adults [108]. Bulb biopsies should be interpreted carefully and sent separately from more distal duodenal samples. Indeed, less than half of all bulb biopsies are high quality; their quality is hampered by the presence of Brunner glands and lymphoid tissue, peptic duodenitis, and gastric metaplasia. Furthermore, villi are smaller in the bulb and can be misinterpreted as atrophic [109, 110]. Finally, biopsies should be collected one-bite (rather than double-bite) at each pass of the forceps, since this decreases the risk of losing specimens, increases (3-fold) the chance of good orientation, and minimizes the risk of tangential biopsies that overestimate mucosal atrophy [111, 112]. Duodenal biopsies should be performed under a gluten-containing diet to avoid false negatives [90].

Histopathological findings characteristic of CD are intraepithelial lymphocytosis (≥25 IEL/100 enterocytes when sections are 3–4 um), crypt hyperplasia, and villous atrophy [90, 113]. A normal histology presents a gradient of IEL (more numerous at the base of the villi and decreasing toward the tip), and the villous:crypt ratio is 3–5:1 [114]. Histological abnormalities are classified according to the Marsh scale, modified by Oberhuber [113] as shown in Table 3.

Table 3.

Modified Marsh classification

Modified Marsh classification
Modified Marsh classification

Children tend to present, more frequently, mucosal atrophy (Marsh 3 lesions) on duodenal biopsies, whereas it is common to diagnose adults without villous atrophy and an inflammatory pattern with IEL (Marsh 1 or 2) [115].

A positive serology associated with a compatible histology (Marsh 2–3) confirms the CD diagnosis [73, 116].

Even though genetic testing is not required for the diagnosis of CD, it may be important to exclude CD, since the absence of HLA-DQ2/8 has a negative predictive value of virtually 100% [117]. This is particularly useful in seronegative patients, patients on a GFD who are unable/unwilling to undergo a gluten challenge, or those who refuse endoscopy [73, 92, 93, 118].

Research on CD is moving toward an endoscopy-free diagnosis of CD. Keeping that in mind, a study found a positive predictive value of 100% with the triple combination of a positive genetic test, positive anti-EMA, and over 10-fold increased anti-tTG titers [119]. In fact, recent European guidelines state that, in children, a duodenal biopsy may not be required if anti-tTG IgA is more than 10 times the upper limit of normal and anti-EMA IgA is positive in a second blood sample. In such cases, a serology-based diagnosis can be established even in the absence of symptoms and without genetic testing. On the other hand, when anti-tTG IgA titles are positive but low, duodenal biopsy should always be performed [84].

Furthermore, several noninvasive markers, such as intestinal fatty acid binding protein (I-FABP), a marker of enterocyte injury, are currently being evaluated. Patients with CD present higher serum levels compared to controls, which correlate with mucosal atrophy. I-FABP levels normalize after a GFD in 80% of children but not in adults [120]. Some studies also suggest a role of I-FABP in assessing adherence to a GFD and accidental gluten ingestion [121].

Another promising technique is flow cytometry that recognizes blood CD4+ T cells that bind to HLA-DQ-gluten tetramers. Preliminar studies have shown a very good accuracy in differenciating CD patients from controls, even on a GFD [122, 123].

Diagnostic Challenges

Seronegative-CD refers to a compatible histology and HLA, with a negative serology, and corresponds to 2% of CD patients [124, 125]. To confirm seronegative CD, the histology must improve after GFD. However, GFD is advised only after excluding other diagnoses, since seronegative CD accounts for <30% of seronegative villous atrophy or epithelial lymphocytosis [90, 126, 127]. As such, these should be excluded: autoimmune enteropathy (anti-enterocyte antibody positive), common variable immunodeficiency, Crohn disease, eosinophilic gastroenteritis, infectious diseases (Whipple disease, G.lamblia, tuberculosis, HIV-associated enteropathy, and tropical sprue), bacterial overgrowth, lymphoproliferative diseases, and drug-associated enteropathy. The drugs most frequently implicated are nonsteroidal anti-inflammatory drugs, immunosuppressors (azathioprine, mycophenolate mofetil, and methotrexate), and angiotensin receptor antagonists, in particular olmesartan, which is responsible for one fifth of seronegative duodenal-atrophy cases in the USA [116, 128-130]. In CD, IEL is composed solely of CD8+ T cells, whereas in non-CD villous atrophy IEL has mixed CD8+ and CD4+ T cells. CD-associated lymphocytosis is also suggested when over 5% of T-cell receptors in IEL are γ/δ and when the base-tip decrescendo gradient is lost [90, 114, 131]. Importantly, non-CD mucosal atrophy reverts spontaneously, without GFD, in over two thirds of patients [126].

Compared to seropositive patients, seronegative CD patients tend to be older (age 49 vs. 36 year) but they present more frequently the classic phenotype [125]. The physiopathology of seronegative CD is not yet clear, but some studies have suggested a high antibody-antigen binding affinity entrapping antibodies in the lamina propria away from the bloodstream. Accordingly, detection of tTG-anti-tTG immunocomplexes in the mucosa can help to identify these patients [132]. Other explanations for seronegative CD are immune system immaturity [133], selective IgA deficiency, a diet poor in gluten, treatment with immunossupressors, and refractory long-term CD [126].

Potential CD (PCD) refers to seropositive patients with a normal duodenal mucosa (Marsh 0) or intraepithelial lymphocytosis (Marsh 1) without crypt hyperplasia or villous atrophy. PCD accounts for 10% of CD patients [93]. Whereas over 80% of children are asymptomatic [134, 135], the majority of adults (79%) with PCD are symptomatic, mostly with a nonclassic phenotype [136]. Symptomatic PCD patients should be kept on a GFD, since it results in clinical improvement. The management of asymptomatic PCD patients is less straightforward, since the progression rate to overt CD is low, i.e., 13% in 10 years [137]. Asymptomatic PCD patients may maintain a gluten-containing diet, with evaluation every 6 months for symptoms and serology and a duodenal biopsy every 2 years if there is a persistently positive serology [136].

Patients on a GFD prior to CD diagnosis may be tested for HLA since the absence of HLA-DQ2/8 excludes CD. In the presence of HLA-DQ2/8, patients should repeat the diagnostic workup after a gluten challenge [138]. Traditionally, a gluten challenge consists of consumption of 7.5 g/day of gluten for 6–8 weeks; however, 3 g/day of gluten (equivalent to 2 slices of bread) is as effective. For patients who cannot tolerate a long gluten challenge, recent studies suggest that 2 weeks may be enough. One caveat is that, whereas histology can be performed immediately after the challenge, serology must be postponed 2 more weeks after the 2-week challenge. This approach allows a correct diagnosis in more than 75% of CD patients [138].

Non-celiac gluten sensitivity (NCGS) is a functional disorder that must be differentiated from CD. NCGS is 6 times more prevalent than CD [139], and it is more frequent in females in their second or third decade [140]. Clinical manifestations are elicited by gluten ingestion and they are similar to CD [141]; however, the kinetics between gluten ingestion and symptoms is much faster; intestinal or extra-intestinal symptoms develop and resolve hours to days after gluten ingestion or eviction [142, 143]. Furthermore, NCGS is not associated with autoimmune disorders. NCGS diagnosis is clinical with demonstration of symptoms resolution with a GFD, and recurrence after rechallenge, and requiring exclusion of CD and wheat allergy [141, 144]. The pathogenesis is unknown, though it is probably multifactorial, resulting from an interplay between the environment (other components of wheat), intestinal barrier dysfunction, gut dysbiota, and diregulated innate imune responses [140].

A lifelong GFD is the only proven treatment and is recommended for classical, nonclassical, seronegative CD, symptomatic PCD, and HD or gluten ataxia [93]. GFD is not recommended for asymptomatic adults with PCD, since only a minority of these patients will develop villus atrophy [136].

A GFD consists of a strict elimination of wheat (and its gluten-containing derivatives bulgur, couscous, and seitan) [89], rye, and barley [145]. Elimination of oats is not so straightforward. In fact, oats contain avenin, a peptid related to gluten that may elicit similar immune reactions. Oats can also induce symptoms by an increase in fiber content. Hence, the oat intake should not exceed 50–60 g/day and patients should be clinically and serologically monitored. Oats should be avoided in severe disease [146].

The tolerable amount of gluten is variable, but as little as 1/100th of a slice of bread (around 50 mg of gluten) is sufficient to induce mucosal atrophy. Gluten-free is defined as <20 ppm of gluten (around 6 mg/day)[147, 148]. Patients should be aware of nondietary potential sources of gluten contamination such as tooth paste and lipstick.

Gastrointestinal symptoms improve after 1 month and usually disappear after 6 months on a GFD [149]. Most patients become seronegative after 6 months on a GFD and only 17% remain seropositive after 1 year [150, 151], suggesting gluten contamination [73]. Anti-tTG IgA is the preferred serological test to monitor GFD adherence. Histological normalization takes longer, particularly in adults, in whom it takes 2–5 years [152]. Only 66% of patients on a GFD achieve a total histological recovery after 1 year, in contrast with the expected recovery in 95% of children [153].

A GFD can also improve extraintestinal manifestations and CD-related conditions. However, some manifestations such as enamel defects and osteopenia may be irreversible or just partially corrected [66, 154].

The GFD should be lifelong, even if the patient acquires a clinical tolerance to gluten. Although 20% of patients maintain histological remission after gluten reintroduction, IEL and a positive serology tend to remain, and those patients are at an increased risk for extraintestinal manifestations and late relapse [155]. Importantly, strict adherence to a GFD is low, i.e., 17–48% [156, 157], and mortality seems to increase 5-fold in patients who do not comply with a GFD [158].

Alternative therapies are under investigation but none has shown sufficient efficacy yet to enter clinical practice. Investigational drugs include genetically modified less immunogenic wheat strains, prolyl endopeptidases, nonabsorbable polymers with a high affinity for gliadin, drugs that act on intestinal permeability gluten deamination, and HLA inhibitors, among others [159].

Patients should be monitored at 6 months and then yearly for GFD adherence, symptoms, serology, a micronutrient deficiency, and associated conditions. Laboratorial tests should include anti-tTG IgA, a full blood count, iron, folic acid, vitamin B12, calcium, vitamin D, thyroid function, and anti-thyroid antibodies [26, 152]. Follow-up endoscopy is advised for persistent or relapsing symptoms despite a GFD [82]. Osteodensitometry should be assessed every 1–2 years [89]. Lastly, vaccination against pneumococci, Haemophilus influenza, and meningococci are strongly recommended [73].

About 1.5% of CD patients progress to refractory CD (RCD), defined as persistence of clinical malabsorption and villous atrophy, after 1 year on GFD, after exclusion of other causes for villous atrophy or malignancy [116]. The main cause of persistent villous atrophy is inadvertent gluten ingestion. Other conditions, i.e., lactose intolerance, irritable bowel syndrome, small bowel bacterial overgrowth, pancreatic insufficiency, and microscopic colitis, should be excluded [83].

RCD is subclassified into types I and II, according to phenotype and clonality of IEL. In type I RCD, IEL are phenotypically normal with polyclonality of the T-cell receptor, whereas in typeII T cells are aberrant, lacking surface CD8 and CD3 expression while expressing intracytoplasmatic CD3, and presenting a monoclonal receptor rearrangement. The distinction of these 2 entities is crucial because the treatment and prognosis are different [89, 160, 161]. Type I RCD usually responds to steroids and budesonide or immunomodulators such as azathioprine. Type II RCD is more aggressive and it is associated with ulcerative jejunoileitis, severe malabsorption, a high risk of progression to enteropathy-associated T-cell lymphoma (EATL) (50%, in 5–10 years) [154, 162], and a 5-year survival rate of 44–58% [154, 160]. Type II RCD does not respond to steroids, should not be treated with azathioprine because of concerns of an increase in the risk for EATL, and may require treatment with cladribine or an autologous/allogenic bone marrow transplant. Targeting of IL-15 is a promising therapeutic strategy [163].

Patients with CD, especially long-standing and untreated patients, present a higher risk for EATL and small intestine adenocarcinoma compared to the general population. The 5-year survival rate for EATL is 11%. The risk of developing other malignancies is still an unanswered topic [89, 164-166].

CD patients seem to have a 20% increase in mortality, particularly in those diagnosed as young adults and in the first 2 years after the diagnosis. Of note, increased mortality in CD patients seems to occur even 10 years after the diagnosis [167]. The mortality rate is probably influenced not only by the age at diagnosis but also by the severity of the presentation, the adherence to a GFD, the ammount of gluten intake, and associated conditions [168].

Specific mortality increases in lymphoproliferative disorders, with a 2-fold increase particularly in women over 50 years of age and in the 2 years following the diagnosis. In fact, in a Finnish study on 12,803 CD patients followed for 7 years, 55% of CD patients died from T-cell lymphoma, compared to 3% of the reference population [169]. Globally, however, no increased risk for cancer-related mortality has been proven [166]. Importantly, CD patients seem to have a 5-fold increased risk of dying from infections, particularly sepsis [169].

CD is still an underdiagnosed entity that poses a diagnostic challenge despite having been described, for the first time, almost 2 thousand years ago. It presents a wide range of unspecific signs and symptoms, both gastrointestinal and extraintestinal. Adults tend to be paucisymptomatic, presenting nonclassical symptoms which can also occur in children. As such, even though population-based screening is not recommended, physicians should use an active case-finding strategy with a low threshold for screening.

Diagnosis requires highly accurate serological tests and a compatible duodenal histopathology, although in children duodenal biopsy may be avoided if the anti-tTG is higher than 10 times the upper limit of normal and anti-EMA is positive in a second blood sample. The presence of HLA-DQ2/8 is mandatory for the development of CD, being particularly helpful in excluding CD. Typical histology findings such as villous atrophy and crypt hyperplasia are unspecific and other diseases, such as Crohn disease, infections, and drug-induced duodenitis, must be excluded.

A lifelong GFD is the only treatment with proven efficacy; however, adherence to this diet is very low. As such, a GFD must be emphasized and monitored regularly. CD patients seem to have an increased mortality, most likely if left untreated.

Current and future research on CD should address endoscopy-free diagnostic algorithms, easier monitoring of dietary gluten contamination, and alternative nondietary therapeutic strategies.

The authors have no conflict of interests to declare.

The authors received no financial support for the research, authorship, or publication of this article.

J.C. wrote this review. M.V.M. wrote and corrected this review.

1.
Ludvigsson
JF
,
Leffler
DA
,
Bai
JC
,
Biagi
F
,
Fasano
A
,
Green
PH
, et al
The Oslo definitions for coeliac disease and related terms
.
Gut
.
2013
Jan
;
62
(
1
):
43
52
.
[PubMed]
0017-5749
2.
Dowd
B
,
Walker-Smith
J
.
Letter: samuel Gee, Aretaeus, and the coeliac affection
.
Br Med J
.
1974
May
;
2
(
5916
):
442
.
[PubMed]
0007-1447
3.
Gasbarrini
GB
,
Mangiola
F
,
Gerardi
V
,
Ianiro
G
,
Corazza
GR
,
Gasbarrini
A
.
Coeliac disease: an old or a new disease? History of a pathology
.
Intern Emerg Med
.
2014
Apr
;
9
(
3
):
249
56
.
[PubMed]
1828-0447
4.
Freeman
HJ
.
Celiac disease: a disorder emerging from antiquity, its evolving classification and risk, and potential new treatment paradigms
.
Gut Liver
.
2015
Jan
;
9
(
1
):
28
37
.
[PubMed]
1976-2283
5.
Gee
S
.
On the coeilac affection
.
St Bartholemews Hosp Rep.
1888
;
24
:
17
.
6.
Herter
CA
.
On Infantilism from Chronic Intestinal Infection, characterized by the Overgrowth and Persistence of Flora of the Nursling Period. Bost Med Surg J. New York
.
MacMillan
.
1909
;
160
:
416
.
7.
Yan
D
,
Holt
PR
.
Willem Dicke. Brilliant clinical observer and translational investigator. Discoverer of the toxic cause of celiac disease
.
Clin Transl Sci
.
2009
Dec
;
2
(
6
):
446
8
.
[PubMed]
1752-8054
8.
Haas
SV
.
The value of the banana in the treatment of coeliac disease
.
Am J Dis Child
.
1924
;
24
:
421
37
.0002-922X
9.
van Berge-Henegouwen
GP
,
Mulder
CJ
.
Pioneer in the gluten free diet: Willem-Karel Dicke 1905-1962, over 50 years of gluten free diet
.
Gut
.
1993
Nov
;
34
(
11
):
1473
5
.
[PubMed]
0017-5749
10.
Paulley
JW
.
Observation on the aetiology of idiopathic steatorrhoea; jejunal and lymph-node biopsies
.
BMJ
.
1954
Dec
;
2
(
4900
):
1318
21
.
[PubMed]
0007-1447
11.
Berger
E
,
Burgin-Wolff
A
,
Freudenberg
E.
Diagnostisehe Bewertung des Nachweises yon Gliadin-AntikSrpern bei Ciiliakie Von.
1964
;788–90.
12.
Kilander
AF
,
Dotevall
G
,
Fällström
SP
,
Gillberg
RE
,
Nilsson
,
Tarkowski
A
.
Evaluation of gliadin antibodies for detection of coeliac disease
.
Scand J Gastroenterol
.
1983
May
;
18
(
3
):
377
83
.
[PubMed]
0036-5521
13.
Signer
E
,
Bürgin-Wolff
A
,
Berger
R
,
Birbaumer
A
,
Just
M
.
Antibodies to gliadin as a screening test for coeliac disease. A prospective study
.
Helv Paediatr Acta
.
1979
Feb
;
34
(
1
):
41
52
.
[PubMed]
0018-022X
14.
Dieterich
W
,
Ehnis
T
,
Bauer
M
,
Donner
P
,
Volta
U
,
Riecken
EO
, et al
Identification of tissue transglutaminase as the autoantigen of celiac disease
.
Nat Med
.
1997
Jul
;
3
(
7
):
797
801
.
[PubMed]
1078-8956
15.
Chorzelski
TP
,
Beutner
EH
,
Sulej
J
,
Tchorzewska
H
,
Jablonska
S
,
Kumar
V
, et al
IgA anti-endomysium antibody. A new immunological marker of dermatitis herpetiformis and coeliac disease
.
Br J Dermatol
.
1984
Oct
;
111
(
4
):
395
402
.
[PubMed]
0007-0963
16.
Falchuk
ZM
,
Rogentine
GN
,
Strober
W
.
Predominance of histocompatibility antigen HL-A8 in patients with gluten-sensitive enteropathy
.
J Clin Invest
.
1972
Jun
;
51
(
6
):
1602
5
.
[PubMed]
0021-9738
17.
Parzanese
I
,
Qehajaj
D
,
Patrinicola
F
,
Aralica
M
,
Chiriva-Internati
M
,
Stifter
S
, et al
Celiac disease: from pathophysiology to treatment
.
World J Gastrointest Pathophysiol
.
2017
May
;
8
(
2
):
27
38
.
[PubMed]
2150-5330
18.
Singh
P
,
Arora
A
,
Strand
TA
,
Leffler
DA
,
Catassi
C
,
Green
PH
, et al
Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis
.
Clin Gastroenterol Hepatol
.
2018
Jun
;
16
(
6
):
823
836.e2
.
[PubMed]
1542-3565
19.
Lionetti
E
,
Gatti
S
,
Pulvirenti
A
,
Catassi
C
.
Celiac disease from a global perspective.
Best Pract Res Clin Gastroenterol. Elsevier Ltd;
2015
;29:365–79.
20.
Yuan
J
,
Gao
J
,
Li
X
,
Liu
F
,
Wijmenga
C
,
Chen
H
, et al
The tip of the “celiac iceberg” in China: a systematic review and meta-analysis
.
PLoS One
.
2013
Dec
;
8
(
12
):
e81151
.
[PubMed]
1932-6203
21.
Poddighe
D
,
Turganbekova
A
,
Baymukasheva
D
,
Saduakas
Z
,
Zhanzakova
Z
,
Abdrakhmanova
S
.
Genetic predisposition to celiac disease in Kazakhstan: potential impact on the clinical practice in Central Asia
.
PLoS One
.
2020
Jan
;
15
(
1
):
e0226546
.
[PubMed]
1932-6203
22.
Poddighe
D
,
Rakhimzhanova
M
,
Marchenko
Y
,
Catassi
C
.
Pediatric celiac disease in central and east asia: current knowledge and prevalence
.
Medicina (Kaunas)
.
2019
Jan
;
55
(
1
):
1
8
.
[PubMed]
1648-9144
23.
West
J
,
Fleming
KM
,
Tata
LJ
,
Card
TR
,
Crooks
CJ
.
Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study
.
Am J Gastroenterol
.
2014
May
;
109
(
5
):
757
68
.
[PubMed]
0002-9270
24.
Withoff
S
,
Li
Y
,
Jonkers
I
,
Wijmenga
C
.
Understanding Celiac Disease by Genomics
.
Trends Genet
.
2016
May
;
32
(
5
):
295
308
.
[PubMed]
0168-9525
25.
McAllister
BP
,
Williams
E
,
Clarke
K
.
A Comprehensive Review of Celiac Disease/Gluten-Sensitive Enteropathies. Clin Rev Allergy Immunol
.
Clin Rev Allergy Immunol
.
2018
;
•••
:
1
18
.1080-0549
26.
Lebwohl
B
,
Sanders
DS
,
Green
PH
.
Coeliac disease
.
Lancet
.
2018
Jan
;
391
(
10115
):
70
81
.
[PubMed]
0140-6736
27.
Amil Dias
J
.
Celiac Disease: What Do We Know in 2017?
GE Port J Gastroenterol
.
2017
Nov
;
24
(
6
):
275
8
.
[PubMed]
2341-4545
28.
Vriezinga
SL
,
Auricchio
R
,
Bravi
E
,
Castillejo
G
,
Chmielewska
A
,
Crespo Escobar
P
, et al
Randomized feeding intervention in infants at high risk for celiac disease
.
N Engl J Med
.
2014
Oct
;
371
(
14
):
1304
15
.
[PubMed]
0028-4793
29.
Aronsson
CA
,
Lee
HS
,
Liu
E
,
Uusitalo
U
,
Hummel
S
,
Yang
J
, et al;
TEDDY STUDY GROUP
.
Age at gluten introduction and risk of celiac disease
.
Pediatrics
.
2015
Feb
;
135
(
2
):
239
45
.
[PubMed]
0031-4005
30.
Silano
M
,
Agostoni
C
,
Sanz
Y
,
Guandalini
S
.
Infant feeding and risk of developing celiac disease: a systematic review
.
BMJ Open
.
2016
Jan
;
6
(
1
):
e009163
.
[PubMed]
2044-6055
31.
Pinto-Sánchez
MI
,
Verdu
EF
,
Liu
E
,
Bercik
P
,
Green
PH
,
Murray
JA
, et al
Gluten Introduction to Infant Feeding and Risk of Celiac Disease: Systematic Review and Meta-Analysis
.
J Pediatr
.
2016
Jan
;
168
:
132
143.e3
.
[PubMed]
0022-3476
32.
Lionetti
E
,
Castellaneta
S
,
Francavilla
R
,
Pulvirenti
A
,
Tonutti
E
,
Amarri
S
, et al;
SIGENP (Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition) Working Group on Weaning and CD Risk
.
Introduction of gluten, HLA status, and the risk of celiac disease in children
.
N Engl J Med
.
2014
Oct
;
371
(
14
):
1295
303
.
[PubMed]
0028-4793
33.
Fewtrell
M
,
Bronsky
J
,
Campoy
C
,
Domellöf
M
,
Embleton
N
,
Fidler Mis
N
, et al
Complementary feeding: A position paper by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) committee on nutrition
.
J Pediatr Gastroenterol Nutr
.
2017
Jan
;
64
(
1
):
119
32
.
[PubMed]
0277-2116
34.
Weile
B
,
Cavell
B
,
Nivenius
K
,
Krasilnikoff
PA
.
Striking differences in the incidence of childhood celiac disease between Denmark and Sweden: a plausible explanation
.
J Pediatr Gastroenterol Nutr
.
1995
Jul
;
21
(
1
):
64
8
.
[PubMed]
0277-2116
35.
Szajewska
H
,
Shamir
R
,
Mearin
L
,
Ribes-Koninckx
C
,
Catassi
C
,
Domellöf
M
, et al
Gluten introduction and the risk of coeliac disease: A position paper by the european society for pediatric gastroenterology, hepatology, and nutrition
.
J Pediatr Gastroenterol Nutr
.
2016
Mar
;
62
(
3
):
507
13
.
[PubMed]
0277-2116
36.
Szajewska
H
,
Shamir
R
,
Chmielewska
A
,
Pieścik-Lech
M
,
Auricchio
R
,
Ivarsson
A
, et al;
PREVENTCD Study Group
.
Systematic review with meta-analysis: early infant feeding and coeliac disease—update 2015
.
Aliment Pharmacol Ther
.
2015
Jun
;
41
(
11
):
1038
54
.
[PubMed]
0269-2813
37.
Mearin
ML
.
The prevention of coeliac disease.
Best Pract Res Clin Gastroenterol. Elsevier Ltd;
2015
;29:493–501.
38.
Stene
LC
,
Honeyman
MC
,
Hoffenberg
EJ
,
Haas
JE
,
Sokol
RJ
,
Emery
L
, et al
Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study
.
Am J Gastroenterol
.
2006
Oct
;
101
(
10
):
2333
40
.
[PubMed]
0002-9270
39.
Ludvigsson
JF
,
Murray
JA
.
Epidemiology of Celiac Disease.
Gastroenterol Clin North Am. Elsevier Inc;
2019
;48:1–18.
40.
Nellikkal
SS
,
Hafed
Y
,
Larson
JJ
,
Murray
JA
,
Absah
I
.
High Prevalence of Celiac Disease Among Screened First-Degree Relatives
.
Mayo Clin Proc
.
2019
Sep
;
94
(
9
):
1807
13
.
[PubMed]
0025-6196
41.
Singh
P
,
Arora
S
,
Lal
S
,
Strand
TA
,
Makharia
GK
.
Risk of celiac disease in the first- and second-degree relatives of patients with celiac disease: A systematic review and meta-analysis. Am J Gastroenterol
.
Am J Gastroenterol
.
2015
Nov
;
110
(
11
):
1539
48
.
[PubMed]
0002-9270
42.
Pham-Short
A
,
Donaghue
KC
,
Ambler
G
,
Phelan
H
,
Twigg
S
,
Craig
ME
.
Screening for celiac disease in type 1 diabetes: A systematic review
.
Pediatrics
.
2015
Jul
;
136
(
1
):
e170
6
.
[PubMed]
0031-4005
43.
Elli
L
,
Bonura
A
,
Garavaglia
D
,
Rulli
E
,
Floriani
I
,
Tagliabue
G
, et al
Immunological comorbity in coeliac disease: associations, risk factors and clinical implications
.
J Clin Immunol
.
2012
Oct
;
32
(
5
):
984
90
.
[PubMed]
0271-9142
44.
Meini
A
,
Pillan
NM
,
Villanacci
V
,
Monafo
V
,
Ugazio
AG
,
Plebani
A
.
Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy, Asthma Immunol. American College of Allergy
.
Asthma & Immunology
.
1996
;
77
(
4
):
333
6
.
45.
Carnicer
J
,
Farré
C
,
Varea
V
,
Vilar
P
,
Moreno
J
,
Artigas
J
.
Prevalence of coeliac disease in Down’s syndrome.
2001
;263–7.
46.
Mårild
K
,
Størdal
K
,
Hagman
A
,
Ludvigsson
JF
.
Turner syndrome and celiac disease: A case-control study
.
Pediatrics
.
2016
Feb
;
137
(
2
):
e20152232
.
[PubMed]
0031-4005
47.
Guandalini
S
,
Assiri
A
.
Celiac disease: a review
.
JAMA Pediatr
.
2014
Mar
;
168
(
3
):
272
8
.
[PubMed]
2168-6203
48.
Kagnoff
MF
.
Celiac disease: pathogenesis of a model immunogenetic disease
.
J Clin Invest
.
2007
Jan
;
117
(
1
):
41
9
.
[PubMed]
0021-9738
49.
Kagnoff
MF
.
Overview and pathogenesis of celiac disease
.
Gastroenterology
.
2005
Apr
;
128
(
4
Suppl 1
):
S10
8
.
[PubMed]
0016-5085
50.
Balakireva
AV
,
Zamyatnin
AA
.
Properties of gluten intolerance: gluten structure, evolution, pathogenicity and detoxification capabilities
.
Nutrients
.
2016
Oct
;
8
(
10
):
8
.
[PubMed]
2072-6643
51.
Shan
L
,
Molberg
Ø
,
Parrot
I
,
Hausch
F
,
Filiz
F
,
Gray
GM
, et al
Structural basis for gluten intolerance in Celiac Sprue.
Science (80-) .
2002
;297:2275–9.
52.
Stamnaes
J
,
Sollid
LM
.
Celiac disease: autoimmunity in response to food antigen
.
Semin Immunol
.
2015
Sep
;
27
(
5
):
343
52
.
[PubMed]
1044-5323
53.
Leonard
MM
,
Sapone
A
,
Catassi
C
,
Fasano
A
.
Celiac disease and nonceliac gluten sensitivity: A review. JAMA -
.
JAMA
.
2017
Aug
;
318
(
7
):
647
56
.
[PubMed]
0098-7484
54.
Lammers
KM
,
Lu
R
,
Brownley
J
,
Lu
B
,
Gerard
C
,
Thomas
K
, et al
Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3
.
Gastroenterology
.
2008
Jul
;
135
(
1
):
194
204.e3
.
[PubMed]
0016-5085
55.
Rescigno
M
,
Di Sabatino
A
.
Dendritic cells in intestinal homeostasis and disease
.
J Clin Invest
.
2009
Sep
;
119
(
9
):
2441
50
.
[PubMed]
0021-9738
56.
Xia
J
,
Sollid
LM
,
Khosla
C
.
Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2
.
Biochemistry
.
2005
Mar
;
44
(
11
):
4442
9
.
[PubMed]
0006-2960
57.
Sollid
LM
.
The roles of MHC class II genes and post-translational modification in celiac disease
.
Immunogenetics
.
2017
Aug
;
69
(
8-9
):
605
16
.
[PubMed]
0093-7711
58.
du Pré
MF
,
Sollid
LM
.
T-cell and B-cell immunity in celiac disease
.
Best Pract Res Clin Gastroenterol
.
2015
Jun
;
29
(
3
):
413
23
.
[PubMed]
1521-6918
59.
Poddighe
D
,
Rebuffi
C
,
De Silvestri
A
,
Capittini
C
.
Carrier frequency of HLA-DQB1*02 allele in patients affected with celiac disease: A systematic review assessing the potential rationale of a targeted allelic genotyping as a first-line screening
.
World J Gastroenterol
.
2020
Mar
;
26
(
12
):
1365
81
.
[PubMed]
1007-9327
60.
Karinen
H
,
Kärkkäinen
P
,
Pihlajamäki
J
,
Janatuinen
E
,
Heikkinen
M
,
Julkunen
R
, et al
Gene dose effect of the DQB1*0201 allele contributes to severity of coeliac disease
.
Scand J Gastroenterol
.
2006
Feb
;
41
(
2
):
191
9
.
[PubMed]
0036-5521
61.
Jabri
B
,
Sollid
LM
.
Tissue-mediated control of immunopathology in coeliac disease
.
Nat Rev Immunol
.
2009
Dec
;
9
(
12
):
858
70
.
[PubMed]
1474-1733
62.
Pender
SL
,
Tickle
SP
,
Docherty
AJ
,
Howie
D
,
Wathen
NC
,
MacDonald
TT
.
A major role for matrix metalloproteinases in T cell injury in the gut
.
J Immunol
.
1997
Feb
;
158
(
4
):
1582
90
.
[PubMed]
0022-1767
63.
Bajaj-Elliott
M
,
Poulsom
R
,
Pender
SL
,
Wathen
NC
,
MacDonald
TT
.
Interactions between stromal cell—derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia
.
J Clin Invest
.
1998
Oct
;
102
(
8
):
1473
80
.
[PubMed]
0021-9738
64.
Sollid
LM
,
Molberg
O
,
McAdam
S
,
Lundin
KE
.
Autoantibodies in coeliac disease: tissue transglutaminase—guilt by association?
Gut
.
1997
Dec
;
41
(
6
):
851
2
.
[PubMed]
0017-5749
65.
Fernández
A
,
González
L
,
de-la-Fuente
J
.
Coeliac disease: clinical features in adult populations
.
Rev Esp Enferm Dig
.
2010
Jul
;
102
(
8
):
466
71
.
[PubMed]
1130-0108
66.
Laurikka
P
,
Nurminen
S
,
Kivelä
L
,
Kurppa
K
.
Extraintestinal manifestations of celiac disease: early detection for better long-term outcomes
.
Nutrients
.
2018
Aug
;
10
(
8
):
1
14
.
[PubMed]
2072-6643
67.
Hadjivassiliou
M
,
Sanders
DD
,
Aeschlimann
DP
.
Gluten-related disorders: gluten ataxia
.
Dig Dis
.
2015
;
33
(
2
):
264
8
.
[PubMed]
0257-2753
68.
Bushara
KO
.
Neurologic presentation of celiac disease
.
Gastroenterology
.
2005
Apr
;
128
(
4
Suppl 1
):
S92
7
.
[PubMed]
0016-5085
69.
Freeman
HJ
.
Neurological disorders in adult celiac disease
.
Can J Gastroenterol
.
2008
Nov
;
22
(
11
):
909
11
.
[PubMed]
0835-7900
70.
Hadjivassiliou
M
,
Rao
DG
,
Grìnewald
RA
,
Aeschlimann
DP
,
Sarrigiannis
PG
,
Hoggard
N
, et al
Neurological dysfunction in coeliac disease and non-coeliac gluten sensitivity
.
Am J Gastroenterol
.
2016
Apr
;
111
(
4
):
561
7
.
[PubMed]
0002-9270
71.
Mearns
ES
,
Taylor
A
,
Thomas Craig
KJ
,
Puglielli
S
,
Leffler
DA
,
Sanders
DS
, et al
Neurological manifestations of neuropathy and ataxia in celiac disease: A systematic review
.
Nutrients
.
2019
Feb
;
11
(
2
):
380
.
[PubMed]
2072-6643
72.
Reunala
T
,
Salmi
TT
,
Hervonen
K
,
Kaukinen
K
,
Collin
P
.
Dermatitis herpetiformis: A common extraintestinal manifestation of coeliac disease
.
Nutrients
.
2018
May
;
10
(
5
):
1
9
.
[PubMed]
2072-6643
73.
Husby
S
,
Koletzko
S
,
Korponay-Szabó
IR
,
Mearin
ML
,
Phillips
A
,
Shamir
R
, et al;
ESPGHAN Working Group on Coeliac Disease Diagnosis
;
ESPGHAN Gastroenterology Committee
;
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition
.
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease
.
J Pediatr Gastroenterol Nutr
.
2012
Jan
;
54
(
1
):
136
60
.
[PubMed]
0277-2116
74.
Pellegrini
FP
,
Marinoni
M
,
Frangione
V
,
Tedeschi
A
,
Gandini
V
,
Ciglia
F
, et al
Down syndrome, autoimmunity and T regulatory cells
.
Clin Exp Immunol
.
2012
Sep
;
169
(
3
):
238
43
.
[PubMed]
0009-9104
75.
Kahaly
GJ
,
Frommer
L
,
Schuppan
D
.
Celiac disease and endocrine autoimmunity - the genetic link
.
Autoimmun Rev
.
2018
Dec
;
17
(
12
):
1169
75
.
[PubMed]
1568-9972
76.
Ventura
A
,
Magazzù
G
,
Greco
L
;
SIGEP Study Group for Autoimmune Disorders in Celiac Disease
.
Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease
.
Gastroenterology
.
1999
Aug
;
117
(
2
):
297
303
.
[PubMed]
0016-5085
77.
Rodrigues
F
,
Bachmeyer
C
.
Coeliac disease and dermatitis herpetiformis
.
Lancet
.
2018
Sep
;
392
(
10151
):
916
.
[PubMed]
0140-6736
78.
Sørensen
HT
,
Thulstrup
AM
,
Blomqvist
P
,
Nørgaard
B
,
Fonager
K
,
Ekbom
A
.
Risk of primary biliary liver cirrhosis in patients with coeliac disease: danish and Swedish cohort data
.
Gut
.
1999
May
;
44
(
5
):
736
8
.
[PubMed]
0017-5749
79.
Ludvigsson
JF
,
Elfström
P
,
Broomé
U
,
Ekbom
A
,
Montgomery
SM
.
Celiac disease and risk of liver disease: a general population-based study
.
Clin Gastroenterol Hepatol
.
2007
Jan
;
5
(
1
):
63
69.e1
.
[PubMed]
1542-3565
80.
Korponay-Szabó
IR
,
Dahlbom
I
,
Laurila
K
,
Koskinen
S
,
Woolley
N
,
Partanen
J
, et al
Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac disease in selective IgA deficiency
.
Gut
.
2003
Nov
;
52
(
11
):
1567
71
.
[PubMed]
0017-5749
81.
Kumar
V
,
Jarzabek-Chorzelska
M
,
Sulej
J
,
Karnewska
K
,
Farrell
T
,
Jablonska
S
.
Celiac disease and immunoglobulin a deficiency: how effective are the serological methods of diagnosis?
Clin Diagn Lab Immunol
.
2002
Nov
;
9
(
6
):
1295
300
.
[PubMed]
1071-412X
82.
Rubio-Tapia
A
,
Hill
ID
,
Kelly
CP
,
Calderwood
AH
,
Murray
JA
;
American College of Gastroenterology
.
ACG clinical guidelines: diagnosis and management of celiac disease
.
Am J Gastroenterol
.
2013
May
;
108
(
5
):
656
76
.
[PubMed]
0002-9270
83.
Al-Toma
A
,
Volta
U
,
Auricchio
R
,
Castillejo
G
,
Sanders
DS
,
Cellier
C
, et al
European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders
.
United European Gastroenterol J
.
2019
Jun
;
7
(
5
):
583
613
.
[PubMed]
2050-6406
84.
Husby
S
,
Koletzko
S
,
Korponay-Szabó
I
,
Kurppa
K
,
Mearin
ML
,
Ribes-Koninckx
C
, et al
European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020
.
J Pediatr Gastroenterol Nutr
.
2020
Jan
;
70
(
1
):
141
56
.
[PubMed]
0277-2116
85.
Irvine
AJ
,
Chey
WD
,
Ford
AC
.
Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis
.
Am J Gastroenterol
.
2017
Jan
;
112
(
1
):
65
76
.
[PubMed]
0002-9270
86.
Downey
L
,
Houten
R
,
Murch
S
,
Longson
D
,
Abuzakouk
M
,
Briggs
S
, et al;
Guideline Development Group
.
Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance
.
BMJ
.
2015
Sep
;
351
:
h4513
.
[PubMed]
0959-8138
87.
Ludvigsson
JF
,
Card
TR
,
Kaukinen
K
,
Bai
J
,
Zingone
F
,
Sanders
DS
, et al
Screening for celiac disease in the general population and in high-risk groups
.
United European Gastroenterol J
.
2015
Apr
;
3
(
2
):
106
20
.
[PubMed]
2050-6406
88.
Leffler
DA
,
Kelly
CP
.
The cost of a loaf of bread in symptomless celiac disease
.
Gastroenterology
.
2014
Sep
;
147
(
3
):
557
9
.
[PubMed]
0016-5085
89.
Elli
L
,
Ferretti
F
,
Orlando
S
,
Vecchi
M
,
Monguzzi
E
,
Roncoroni
L
, et al
Management of celiac disease in daily clinical practice.
Eur J Intern Med. Elsevier;
2018
;61:15–24.
90.
Kowalski
K
,
Mulak
A
,
Jasińska
M
,
Paradowski
L
.
Diagnostic challenges in celiac disease
.
Adv Clin Exp Med
.
2017
Jul
;
26
(
4
):
729
37
.
[PubMed]
1899-5276
91.
Schyum
AC
,
Rumessen
JJ
.
Serological testing for celiac disease in adults
.
United European Gastroenterol J
.
2013
Oct
;
1
(
5
):
319
25
.
[PubMed]
2050-6406
92.
Korponay-Szabó
IR
,
Troncone
R
,
Discepolo
V
.
Adaptive diagnosis of coeliac disease
.
Best Pract Res Clin Gastroenterol
.
2015
Jun
;
29
(
3
):
381
98
.
[PubMed]
1521-6918
93.
Lau
MS
,
Sanders
DS
.
Optimizing the diagnosis of celiac disease
.
Curr Opin Gastroenterol
.
2017
May
;
33
(
3
):
173
80
.
[PubMed]
0267-1379
94.
Hanevik
K
,
Wik
E
,
Langeland
N
,
Hausken
T
.
Transient elevation of anti-transglutaminase and anti-endomysium antibodies in Giardia infection.
Scand J Gastroenterol. Taylor & Francis;
2018
;53:809–12.
95.
Vecchi
M
,
Folli
C
,
Donato
MF
,
Formenti
S
,
Arosio
E
,
de Franchis
R
.
High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source
.
Scand J Gastroenterol
.
2003
Jan
;
38
(
1
):
50
4
.
[PubMed]
0036-5521
96.
Peracchi
M
,
Trovato
C
,
Longhi
M
,
Gasparin
M
,
Conte
D
,
Tarantino
C
, et al
Tissue transglutaminase antibodies in patients with end-stage heart failure
.
Am J Gastroenterol
.
2002
Nov
;
97
(
11
):
2850
4
.
[PubMed]
0002-9270
97.
Castillo
NE
,
Theethira
TG
,
Leffler
DA
.
The present and the future in the diagnosis and management of celiac disease
.
Gastroenterol Rep (Oxf)
.
2015
Feb
;
3
(
1
):
3
11
.
[PubMed]
2052-0034
98.
Emami
MH
,
Karimi
S
,
Nemati
A
.
Do endoscopic markers still play a role in the diagnosis of celiac disease?
Indian J Gastroenterol
.
2008
Sep-Oct
;
27
(
5
):
183
5
.
[PubMed]
0975-0711
99.
Dickey
W
.
Endoscopic markers for celiac disease
.
Nat Clin Pract Gastroenterol Hepatol
.
2006
Oct
;
3
(
10
):
546
51
.
[PubMed]
1743-4378
100.
Ianiro
G
,
Gasbarrini
A
,
Cammarota
G
.
Endoscopic tools for the diagnosis and evaluation of celiac disease
.
World J Gastroenterol
.
2013
Dec
;
19
(
46
):
8562
70
.
[PubMed]
1007-9327
101.
Balaban
DV
,
Popp
A
,
Vasilescu
F
,
Haidautu
D
,
Purcarea
RM
,
Jinga
M
.
Diagnostic yield of endoscopic markers for celiac disease
.
J Med Life
.
2015
Oct-Dec
;
8
(
4
):
452
7
.
[PubMed]
1844-3117
102.
Cammarota
G
,
Pirozzi
GA
,
Martino
A
,
Zuccalà
G
,
Cianci
R
,
Cuoco
L
, et al
Reliability of the “immersion technique” during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia
.
Gastrointest Endosc
.
2004
Aug
;
60
(
2
):
223
8
.
[PubMed]
0016-5107
103.
Dutta
AK
,
Sajith
KG
,
Shah
G
,
Pulimood
AB
,
Simon
EG
,
Joseph
AJ
, et al
Duodenal villous morphology assessed using magnification narrow band imaging correlates well with histology in patients with suspected malabsorption syndrome
.
Dig Endosc
.
2014
Nov
;
26
(
6
):
720
5
.
[PubMed]
0915-5635
104.
Cammarota
G
,
Ianiro
G
,
Sparano
L
,
La Mura
R
,
Ricci
R
,
Larocca
LM
, et al
Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns
.
Dig Dis Sci
.
2013
May
;
58
(
5
):
1287
92
.
[PubMed]
0163-2116
105.
Leong
RW
,
Nguyen
NQ
,
Meredith
CG
,
Al-Sohaily
S
,
Kukic
D
,
Delaney
PM
, et al
In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease
.
Gastroenterology
.
2008
Dec
;
135
(
6
):
1870
6
.
[PubMed]
0016-5085
106.
Penny
HA
,
Mooney
PD
,
Burden
M
,
Patel
N
,
Johnston
AJ
,
Wong
SH
, et al
High definition endoscopy with or without I-Scan increases the detection of celiac disease during routine endoscopy
.
Dig Liver Dis
.
2016
Jun
;
48
(
6
):
644
9
.
[PubMed]
1590-8658
107.
Lewis
SK
,
Semrad
CE
.
Capsule Endoscopy and Enteroscopy in Celiac Disease.
Gastroenterol Clin North Am. Elsevier Inc;
2019
;48:73–84.
108.
McCarty
TR
,
O’Brien
CR
,
Gremida
A
,
Ling
C
,
Rustagi
T
.
Efficacy of duodenal bulb biopsy for diagnosis of celiac disease: a systematic review and meta-analysis
.
Endosc Int Open
.
2018
Nov
;
6
(
11
):
E1369
78
.
[PubMed]
2364-3722
109.
Taavela
J
,
Popp
A
,
Korponay-Szabo
IR
,
Ene
A
,
Vornanen
M
,
Saavalainen
P
, et al
A Prospective Study on the Usefulness of Duodenal Bulb Biopsies in Celiac Disease Diagnosis in Children: urging Caution
.
Am J Gastroenterol
.
2016
Jan
;
111
(
1
):
124
33
.
[PubMed]
0002-9270
110.
Voutilainen
M
,
Juhola
M
,
Färkkilä
M
,
Sipponen
P
.
Gastric metaplasia and chronic inflammation at the duodenal bulb mucosa
.
Dig Liver Dis
.
2003
Feb
;
35
(
2
):
94
8
.
[PubMed]
1590-8658
111.
Padda
S
,
Shah
I
,
Ramirez
FC
.
Adequacy of mucosal sampling with the “two-bite” forceps technique: a prospective, randomized, blinded study
.
Gastrointest Endosc
.
2003
Feb
;
57
(
2
):
170
3
.
[PubMed]
0016-5107
112.
Latorre
M
,
Lagana
SM
,
Freedberg
DE
,
Lewis
SK
,
Lebwohl
B
,
Bhagat
G
, et al
Endoscopic biopsy technique in the diagnosis of celiac disease: one bite or two?
Gastrointest Endosc
.
2015
May
;
81
(
5
):
1228
33
.
[PubMed]
0016-5107
113.
Oberhuber
G
.
Histopathology of celiac disease
.
Biomed Pharmacother
.
2000
Aug
;
54
(
7
):
368
72
.
[PubMed]
0753-3322
114.
Brown
I
,
Mino-Kenudson
M
,
Deshpande
V
,
Lauwers
GY
.
Intraepithelial lymphocytosis in architecturally preserved proximal small intestinal mucosa: an increasing diagnostic problem with a wide differential diagnosis
.
Arch Pathol Lab Med
.
2006
Jul
;
130
(
7
):
1020
5
.
[PubMed]
1543-2165
115.
Ciccocioppo
R
,
Kruzliak
P
,
Cangemi
GC
,
Pohanka
M
,
Betti
E
,
Lauret
E
, et al
The spectrum of differences between childhood and adulthood celiac disease
.
Nutrients
.
2015
Oct
;
7
(
10
):
8733
51
.
[PubMed]
2072-6643
116.
Ludvigsson
JF
,
Bai
JC
,
Biagi
F
,
Card
TR
,
Ciacci
C
,
Ciclitira
PJ
, et al;
BSG Coeliac Disease Guidelines Development Group
;
British Society of Gastroenterology
.
Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology
.
Gut
.
2014
Aug
;
63
(
8
):
1210
28
.
[PubMed]
0017-5749
117.
Sollid
LM
,
Lie
BA
.
Celiac disease genetics: current concepts and practical applications
.
Clin Gastroenterol Hepatol
.
2005
Sep
;
3
(
9
):
843
51
.
[PubMed]
1542-3565
118.
Sciurti
M
,
Fornaroli
F
,
Gaiani
F
,
Bonaguri
C
,
Leandro
G
,
Di Mario
F
, et al
Genetic susceptibilty and celiac disease: what role do HLA haplotypes play?
Acta Biomed
.
2018
Dec
;
89
9-S
:
17
21
.
[PubMed]
2531-6745
119.
Fuchs
V
,
Kurppa
K
,
Huhtala
H
,
Laurila
K
,
Mäki
M
,
Collin
P
, et al
Serology-based criteria for adult coeliac disease have excellent accuracy across the range of pre-test probabilities
.
Aliment Pharmacol Ther
.
2019
Feb
;
49
(
3
):
277
84
.
[PubMed]
0269-2813
120.
Adriaanse
MP
,
Tack
GJ
,
Passos
VL
,
Damoiseaux
JG
,
Schreurs
MW
,
van Wijck
K
, et al
Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies
.
Aliment Pharmacol Ther
.
2013
Feb
;
37
(
4
):
482
90
.
[PubMed]
0269-2813
121.
Adriaanse
MP
,
Leffler
DA
,
Kelly
CP
,
Schuppan
D
,
Najarian
RM
,
Goldsmith
JD
, et al
Serum I-FABP Detects Gluten Responsiveness in Adult Celiac Disease Patients on a Short-Term Gluten Challenge
.
Am J Gastroenterol
.
2016
Jul
;
111
(
7
):
1014
22
.
[PubMed]
0002-9270
122.
Sarna
VK
,
Lundin
KE
,
Mørkrid
L
,
Qiao
SW
,
Sollid
LM
,
Christophersen
A
.
HLA-DQ-Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption
.
Gastroenterology
.
2018
Mar
;
154
(
4
):
886
896.e6
.
[PubMed]
0016-5085
123.
Sarna
VK
,
Skodje
GI
,
Reims
HM
,
Risnes
LF
,
Dahal-Koirala
S
,
Sollid
LM
, et al
HLA-DQ:gluten tetramer test in blood gives better detection of coeliac patients than biopsy after 14-day gluten challenge
.
Gut
.
2018
Sep
;
67
(
9
):
1606
13
.
[PubMed]
0017-5749
124.
Schiepatti
A
,
Biagi
F
,
Fraternale
G
,
Vattiato
C
,
Balduzzi
D
,
Agazzi
S
, et al
Short article: mortality and differential diagnoses of villous atrophy without coeliac antibodies
.
Eur J Gastroenterol Hepatol
.
2017
May
;
29
(
5
):
572
6
.
[PubMed]
0954-691X
125.
Volta
U
,
Caio
G
,
Boschetti
E
,
Giancola
F
,
Rhoden
KJ
,
Ruggeri
E
, et al
Seronegative celiac disease: shedding light on an obscure clinical entity
.
Dig Liver Dis
.
2016
Sep
;
48
(
9
):
1018
22
.
[PubMed]
1590-8658
126.
Aziz
I
,
Peerally
MF
,
Barnes
JH
,
Kandasamy
V
,
Whiteley
JC
,
Partridge
D
, et al
The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000-2015)
.
Gut
.
2017
Sep
;
66
(
9
):
1563
72
.
[PubMed]
0017-5749
127.
Schiepatti
A
,
Sanders
DS
,
Biagi
F
.
Seronegative coeliac disease: clearing the diagnostic dilemma
.
Curr Opin Gastroenterol
.
2018
May
;
34
(
3
):
154
8
.
[PubMed]
0267-1379
128.
Elli
L
,
Branchi
F
,
Sidhu
R
,
Guandalini
S
,
Assiri
A
,
Rinawi
F
, et al
Small bowel villous atrophy: celiac disease and beyond.
Expert Rev Gastroenterol Hepatol. Taylor & Francis;
2017
;11:125–38.
129.
Jansson-Knodell
CL
,
Hujoel
IA
,
Rubio-Tapia
A
,
Murray
JA
.
Not All That Flattens Villi Is Celiac Disease: A Review of Enteropathies
.
Mayo Clin Proc
.
2018
Apr
;
93
(
4
):
509
17
.
[PubMed]
0025-6196
130.
Kamboj
AK
,
Oxentenko
AS
.
Clinical and Histologic Mimickers of Celiac Disease
.
Clin Transl Gastroenterol
.
2017
Aug
;
8
(
8
):
e114
.
[PubMed]
2155-384X
131.
Walker
MM
,
Murray
JA
,
Ronkainen
J
,
Aro
P
,
Storskrubb
T
,
D’Amato
M
, et al
Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study
.
Gastroenterology
.
2010
Jul
;
139
(
1
):
112
9
.
[PubMed]
0016-5085
132.
Salmi
TT
,
Collin
P
,
Korponay-Szabó
IR
,
Laurila
K
,
Partanen
J
,
Huhtala
H
, et al
Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits
.
Gut
.
2006
Dec
;
55
(
12
):
1746
53
.
[PubMed]
0017-5749
133.
Ierardi
E
,
Losurdo
G
,
Piscitelli
D
,
Giorgio
F
,
Sorrentino
C
,
Principi
M
, et al
Seronegative celiac disease: where is the specific setting?
Gastroenterol Hepatol Bed Bench
.
2015
;
8
(
2
):
110
6
.
[PubMed]
2008-2258
134.
Tosco
A
,
Salvati
VM
,
Auricchio
R
,
Maglio
M
,
Borrelli
M
,
Coruzzo
A
, et al
Natural History of Potential Celiac Disease in Children.
Clin Gastroenterol Hepatol. Elsevier Inc.;
2011
;9:320–5.
135.
Auricchio
R
,
Tosco
A
,
Piccolo
E
,
Galatola
M
,
Izzo
V
,
Maglio
M
, et al
Potential celiac children: 9-year follow-up on a gluten-containing diet
.
Am J Gastroenterol
.
2014
Jun
;
109
(
6
):
913
21
.
[PubMed]
0002-9270
136.
Volta
U
,
Caio
G
,
Giancola
F
,
Rhoden
KJ
,
Ruggeri
E
,
Boschetti
E
, et al
Features and Progression of Potential Celiac Disease in Adults.
Clin Gastroenterol Hepatol. Elsevier Ltd;
2016
;14:686-693.e1.
137.
Lionetti
E
,
Castellaneta
S
,
Francavilla
R
,
Pulvirenti
A
,
Naspi Catassi
G
,
Catassi
C
;
SIGENP Working Group of Weaning and CD Risk
.
Long-Term Outcome of Potential Celiac Disease in Genetically at-Risk Children: The Prospective CELIPREV Cohort Study
.
J Clin Med
.
2019
Feb
;
8
(
2
):
186
.
[PubMed]
2077-0383
138.
Leffler
D
,
Schuppan
D
,
Pallav
K
,
Najarian
R
,
Goldsmith
JD
,
Hansen
J
, et al
Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease
.
Gut
.
2013
Jul
;
62
(
7
):
996
1004
.
[PubMed]
0017-5749
139.
Sapone
A
,
Bai
JC
,
Ciacci
C
,
Dolinsek
J
,
Green
PH
,
Hadjivassiliou
M
, et al
Spectrum of gluten-related disorders: consensus on new nomenclature and classification
.
BMC Med
.
2012
Feb
;
10
(
1
):
13
.
[PubMed]
1741-7015
140.
Volta
U
,
De Giorgio
R
,
Caio
G
,
Uhde
M
,
Manfredini
R
,
Alaedini
A
.
Nonceliac Wheat Sensitivity: An Immune-Mediated Condition with Systemic Manifestations
.
Gastroenterol Clin North Am
.
2019
Mar
;
48
(
1
):
165
82
.
[PubMed]
0889-8553
141.
Catassi
C
,
Elli
L
,
Bonaz
B
,
Bouma
G
,
Carroccio
A
,
Castillejo
G
, et al
Diagnosis of non-celiac gluten sensitivity (NCGS): the salerno experts’ criteria
.
Nutrients
.
2015
Jun
;
7
(
6
):
4966
77
.
[PubMed]
2072-6643
142.
Schuppan
D
,
Pickert
G
,
Ashfaq-Khan
M
,
Zevallos
V
.
Non-celiac wheat sensitivity: differential diagnosis, triggers and implications
.
Best Pract Res Clin Gastroenterol
.
2015
Jun
;
29
(
3
):
469
76
.
[PubMed]
1521-6918
143.
Volta
U
,
Caio
G
,
De Giorgio
R
,
Henriksen
C
,
Skodje
G
,
Lundin
KE
.
Non-celiac gluten sensitivity: A work-in-progress entity in the spectrum of wheat-related disorders.
Best Pract Res Clin Gastroenterol. Elsevier Ltd;
2015
;29:477–91.
144.
Mansueto
P
,
Seidita
A
,
D’Alcamo
A
,
Carroccio
A
.
Non-celiac gluten sensitivity: literature review
.
J Am Coll Nutr
.
2014
;
33
(
1
):
39
54
.
[PubMed]
0731-5724
145.
Bascuñán
KA
,
Vespa
MC
,
Araya
M
.
Celiac disease: understanding the gluten-free diet
.
Eur J Nutr
.
2017
Mar
;
56
(
2
):
449
59
.
[PubMed]
1436-6207
146.
Dennis
M
,
Lee
AR
,
McCarthy
T
.
Nutritional Considerations of the Gluten-Free Diet.
Gastroenterol Clin North Am. Elsevier Inc;
2019
;48:53–72.
147.
Akobeng
AK
,
Thomas
AG
.
Systematic review: tolerable amount of gluten for people with coeliac disease
.
Aliment Pharmacol Ther
.
2008
Jun
;
27
(
11
):
1044
52
.
[PubMed]
0269-2813
148.
Hischenhuber
C
,
Crevel
R
,
Jarry
B
,
Mäki
M
,
Moneret-Vautrin
DA
,
Romano
A
, et al
Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease
.
Aliment Pharmacol Ther
.
2006
Mar
;
23
(
5
):
559
75
.
[PubMed]
0269-2813
149.
Oxentenko
AS
,
Murray
JA
.
Celiac Disease: Ten Things That Every Gastroenterologist Should Know. Clin Gastroenterol Hepatol
.
Elsevier, Inc
;
2015
. p.
13
.
150.
Rashid
M
,
Lee
J
.
Serologic testing in celiac disease: practical guide for clinicians
.
Can Fam Physician
.
2016
Jan
;
62
(
1
):
38
43
.
[PubMed]
1715-5258
151.
Zanini
B
,
Lanzarotto
F
,
Mora
A
,
Bertolazzi
S
,
Turini
D
,
Cesana
B
, et al
Five year time course of celiac disease serology during gluten free diet: results of a community based “CD-Watch” program
.
Dig Liver Dis
.
2010
Dec
;
42
(
12
):
865
70
.
[PubMed]
1590-8658
152.
Mulder
CJ
,
Wierdsma
NJ
,
Berkenpas
M
,
Jacobs
MAJM
,
Bouma
G
. Preventing complications in celiac disease: Our experience with managing adult celiac disease. Best Pract Res Clin Gastroenterol. Elsevier Ltd;
2015
;29:459–68.
153.
Galli
G
,
Esposito
G
,
Lahner
E
,
Pilozzi
E
,
Corleto
VD
,
Di Giulio
E
, et al
Histological recovery and gluten-free diet adherence: a prospective 1-year follow-up study of adult patients with coeliac disease
.
Aliment Pharmacol Ther
.
2014
Sep
;
40
(
6
):
639
47
.
[PubMed]
0269-2813
154.
Malamut
G
,
Cellier
C
.
Complications of coeliac disease.
Best Pract Res Clin Gastroenterol. Elsevier Ltd;
2015
;29:451–8.
155.
Matysiak-Budnik
T
,
Malamut
G
,
de Serre
NP
,
Grosdidier
E
,
Seguier
S
,
Brousse
N
, et al
Long-term follow-up of 61 coeliac patients diagnosed in childhood: evolution toward latency is possible on a normal diet
.
Gut
.
2007
Oct
;
56
(
10
):
1379
86
.
[PubMed]
0017-5749
156.
Hall
NJ
,
Rubin
G
,
Charnock
A
.
Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease
.
Aliment Pharmacol Ther
.
2009
Aug
;
30
(
4
):
315
30
.
[PubMed]
0269-2813
157.
Leffler
DA
,
Edwards-George
J
,
Dennis
M
,
Schuppan
D
,
Cook
F
,
Franko
DL
, et al
Factors that influence adherence to a gluten-free diet in adults with celiac disease
.
Dig Dis Sci
.
2008
Jun
;
53
(
6
):
1573
81
.
[PubMed]
0163-2116
158.
Corrao
G
,
Corazza
GR
,
Bagnardi
V
,
Brusco
G
,
Ciacci
C
,
Cottone
M
, et al
Mortality in patients with coeliac disease and their relatives: a cohort study.
2001
;358:356–61.
159.
Costes
LM
,
Meresse
B
,
Cerf-Bensussan
N
,
Samsom
JN
.
The role of animal models in unravelling therapeutic targets in coeliac disease
.
Best Pract Res Clin Gastroenterol
.
2015
Jun
;
29
(
3
):
437
50
.
[PubMed]
1521-6918
160.
Malamut
G
,
Cellier
C
.
Refractory celiac disease: epidemiology and clinical manifestations
.
Dig Dis
.
2015
;
33
(
2
):
221
6
.
[PubMed]
0257-2753
161.
Roshan
B
,
Leffler
DA
,
Jamma
S
,
Dennis
M
,
Sheth
S
,
Falchuk
K
, et al
The incidence and clinical spectrum of refractory celiac disease in a north american referral center
.
Am J Gastroenterol
.
2011
May
;
106
(
5
):
923
8
.
[PubMed]
0002-9270
162.
Nijeboer
P
,
van Wanrooij
R
,
van Gils
T
,
Wierdsma
NJ
,
Tack
GJ
,
Witte
BI
, et al
Lymphoma development and survival in refractory coeliac disease type II: histological response as prognostic factor
.
United European Gastroenterol J
.
2017
Mar
;
5
(
2
):
208
17
.
[PubMed]
2050-6406
163.
Malamut
G
,
Cellier
C.
Refractory Celiac Disease.
Gastroenterol Clin North Am. Elsevier Inc;
2019
;48:137–44.
164.
Catassi
C
,
Bearzi
I
,
Holmes
GK
.
Association of celiac disease and intestinal lymphomas and other cancers
.
Gastroenterology
.
2005
Apr
;
128
(
4
Suppl 1
):
S79
86
.
[PubMed]
0016-5085
165.
Ilus
T
,
Kaukinen
K
,
Virta
LJ
,
Pukkala
E
,
Collin
P
.
Incidence of malignancies in diagnosed celiac patients: a population-based estimate
.
Am J Gastroenterol
.
2014
Sep
;
109
(
9
):
1471
7
.
[PubMed]
0002-9270
166.
Tio
M
,
Cox
MR
,
Eslick
GD
.
Meta-analysis: coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy
.
Aliment Pharmacol Ther
.
2012
Mar
;
35
(
5
):
540
51
.
[PubMed]
0269-2813
167.
Lebwohl
B
,
Green
PH
,
Söderling
J
,
Roelstraete
B
,
Ludvigsson
JF
.
Association Between Celiac Disease and Mortality Risk in a Swedish Population
.
JAMA
.
2020
Apr
;
323
(
13
):
1277
85
.
[PubMed]
0098-7484
168.
Biagi
F
,
Corazza
GR
.
Do different patients with coeliac disease have different mortality rates?
Gut
.
2015
Aug
;
64
(
8
):
1187
8
.
[PubMed]
0017-5749
169.
Koskinen
I
,
Virta
LJ
,
Huhtala
H
,
Ilus
T
,
Kaukinen
K
,
Collin
P
.
Overall and Cause-Specific Mortality in Adult Celiac Disease and Dermatitis Herpetiformis Diagnosed in the 21st Century
.
Am J Gastroenterol
.
2020
Jul
;
115
(
7
):
1117
24
.
[PubMed]
0002-9270
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.